FRESENIUS SE+CO. ADR 1/4 Total Liabilities

Latest as of December 2025: €21.63 Billion EUR ≈ $25.29 Billion USD

FRESENIUS SE+CO. ADR 1/4 total liabilities. Based on the latest financial reports, FRESENIUS SE+CO. ADR 1/4 (FREA) has total liabilities worth €21.63 Billion EUR (≈ $25.29 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See FREA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Total Liabilities of FRESENIUS SE+CO. ADR 1/4 (2021–2025)

Total liabilities of FRESENIUS SE+CO. ADR 1/4 from 2021 to 2025. This chart illustrates how FRESENIUS SE+CO. ADR 1/4's total liabilities have evolved over time, based on quarterly financial data. Check FRESENIUS SE+CO. ADR 1/4 liquid asset ratio to evaluate the company's liquid asset resilience ratio.

FRESENIUS SE+CO. ADR 1/4 Competitors by Total Liabilities

The table below lists competitors of FRESENIUS SE+CO. ADR 1/4 ranked by their total liabilities.

Company Country Total Liabilities
Citizens Financial Group, Inc.
NYSE:CFG
USA $207.65 Billion
Bank Hapoalim
TA:POLI
Israel ILA731.69 Billion
Dollar General Corporation
NYSE:DG
USA $22.86 Billion
Estee Lauder Companies Inc
NYSE:EL
USA $15.67 Billion
Dover Corporation
NYSE:DOV
USA $6.02 Billion
Ecopetrol SA ADR
NYSE:EC
USA $183.21 Trillion
American Water Works
NYSE:AWK
USA $24.79 Billion
SIKA AG UNSP.ADR O.N.
F:SIKB
Germany €8.48 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down FRESENIUS SE+CO. ADR 1/4's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FRESENIUS SE+CO. ADR 1/4 asset portfolio.

Liquidity & Leverage Metrics

FRESENIUS SE+CO. ADR 1/4 Total Liabilities Ratios Explained

FRESENIUS SE+CO. ADR 1/4 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.32 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.52 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how FRESENIUS SE+CO. ADR 1/4's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for FRESENIUS SE+CO. ADR 1/4 (2021–2025)

The table below shows the annual total liabilities of FRESENIUS SE+CO. ADR 1/4 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €21.63 Billion
≈ $25.29 Billion
-7.02%
2024-12-31 €23.26 Billion
≈ $27.19 Billion
-9.26%
2023-12-31 €25.63 Billion
≈ $29.97 Billion
-41.98%
2022-12-31 €44.18 Billion
≈ $51.65 Billion
+3.53%
2021-12-31 €42.67 Billion
≈ $49.89 Billion
--

About FRESENIUS SE+CO. ADR 1/4

F:FREA Germany Medical Care Facilities
Market Cap
$26.87 Billion
€22.98 Billion EUR
Market Cap Rank
#990 Global
#223 in Germany
Share Price
€10.20
Change (1 day)
-1.92%
52-Week Range
€9.90 - €20.00
All Time High
€20.00
About

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more